



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 1 (W1 B1)
Corrections, see
Bibliography INID code(s) 73

(51) Int Cl.:
A61K 8/43 (2006.01) C07D 295/13 (2006.01)

(86) International application number:
PCT/US2012/061205

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(87) International publication number:
WO 2013/059735 (25.04.2013 Gazette 2013/17)

(45) Date of publication and mention
of the grant of the patent:
01.05.2019 Bulletin 2019/18

(21) Application number: **12841245.9**

(22) Date of filing: **19.10.2012**

(54) **LOCALIZED MODULATION OF TISSUES AND CELLS TO ENHANCE THERAPEUTIC EFFECTS INCLUDING RENAL DENERVATION**

LOKALISIERTE MODULATION VON GEWEBE UND ZELLEN ZUR VERBESSERUNG DER
THERAPEUTISCHEN WIRKUNG EINSCHLIESSLICH NIERENDENERVIERUNG

MODULATION LOCALISÉE DE TISSUS ET DE CELLULES POUR AMÉLIORER DES EFFETS
THÉRAPEUTIQUES COMPRENANT LA DÉNERVATION RÉNALE

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR

(56) References cited:
WO-A1-2012/161875 WO-A2-01/43775
US-A- 3 271 448 US-A- 3 301 755
US-A- 3 723 463 US-A- 3 911 125
US-A- 4 496 573 US-A- 6 009 875
US-A1- 2011 104 061 US-B1- 6 787 569
US-B2- 7 022 214 US-B2- 7 074 834

(30) Priority: **19.10.2011 US 201161548822 P**

(43) Date of publication of application:
27.08.2014 Bulletin 2014/35

(60) Divisional application:
19164184.4

(73) Proprietor: **Mercator Medsystems, Inc.**
Emeryville, CA 94608 (US)

(72) Inventor: **SEWARD, Kirk, P.**
San Francisco, CA 94107 (US)

(74) Representative: **MacLean, Martin Robert et al**
Mathys & Squire LLP
The Shard
32 London Bridge Street
London SE1 9SG (GB)

- **DEMAS ET AL.: 'Novel method for localized, functional sympathetic nervous system denervation of peripheral tissue using guanethidine' JOURNAL OF NEUROSCIENCE METHODS vol. 112, no. 1, 2001, pages 21 - 28, XP055037343**
- **WAHBI, ABDEL-AZIZ M. ET AL.: 'Spectrofluorimetric determination of guanethidine sulphate, guanfacine hydrochloride, guanoclor sulphate and guanoxan sulphate in tablets and biological fluids, using benzoin' MICROCHIMICA ACTA vol. 111, 1993, pages 83 - 91, XP005506628**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).